Q3 2015 13F Holders as of 9/30/2015
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
34.9M
-
Shares change
-
+2.25M
-
Total reported value, excl. options
-
$3.36B
-
Value change
-
+$212M
-
Put/Call ratio
-
1.63
-
Number of buys
-
114
-
Number of sells
-
-51
-
Price
-
$96.31
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q3 2015
190 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q3 2015.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.9M shares
of 96M outstanding shares and own 36.34% of the company stock.
Largest 10 shareholders include FMR LLC (5.8M shares), Capital Research Global Investors (4.74M shares), VANGUARD GROUP INC (2.12M shares), WELLINGTON MANAGEMENT GROUP LLP (1.88M shares), WELLS FARGO & COMPANY/MN (1.55M shares), BlackRock Fund Advisors (1.48M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.36M shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (1.25M shares), STATE STREET CORP (857K shares), and BlackRock Institutional Trust Company, N.A. (854K shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.